DEARBORN PARTNERS

Another Dearborn Partners Core Rising Dividend SMA Portfolio Increase: Abbott Laboratories

On December 10, 2021, Abbott Laboratories (ABT) announced a 4.4% increase in its quarterly dividend per share to \$0.47 (\$1.88 annually) from \$0.45 (\$1.80 annually). The cash dividend will be paid on February 15, 2022 to holders of record as of January 14, 2022. This is the 50th consecutive annual increase in the dividend paid by Abbott Laboratories.

From the Press Release: "Fifty years of dividend growth reflects the consistently strong performance of our diversified business model," said Robert B. Ford, president and chief executive officer, Abbott. "It exemplifies our longstanding commitment to delivering sustainable growth that fuels innovation as well as shareholder returns."

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Abbott's 109,000 colleagues serve people in more than 160 countries.

Abbott Laboratories is in the Health Care sector of our Dearborn Partners Core Rising Dividend separately managed account (SMA) portfolio. All 49 companies in our Core Rising Dividend SMA portfolio have announced dividend increases in year 2021. Forty-nine companies announced 54 dividend increases averaging about 9.8% more than these companies paid a year earlier. No companies in this portfolio have reduced or suspended dividends so far this year.

Thank you for your continued interest in our Dearborn Partners Rising Dividend Strategy. The Dearborn Partners Rising Dividend team wishes you and your loved ones a joyous holiday season. We are truly grateful for your partnership. We look forward to 2022 and what we hope will be a year full of good health, happiness, prosperity, and lots of rising dividends!

This dividend increase announcement is not a complete description of, nor a recommendation to invest in, any investment strategy (the "Strategy") mentioned herein. It is for informational purposes only and does not constitute an offer to sell nor a solicitation to buy, is not a recommendation regarding any securities transaction, nor is it an offer to provide advisory or other services by Dearborn Partners, L.L.C. The information contained in this writing should not be construed as financial or investment advice on any subject matter. Past performance is no guarantee of future results. There is no assurance the Strategy will be profitable, achieve its objectives, be suitable for you, or not incur losses. Some of the information herein has been obtained from third party sources. We believe such information is reliable but we have not in each case verified its accuracy or completeness. Any opinions herein are as of the date of this report and are subject to change without notice. Dividends are not quaranteed and must be authorized by the company's board of directors. There is no assurance that any Rising Dividend portfolio company will increase its dividend, or not reduce its dividend, or not have a significant decrease in its stock price. Dividend yield is one component of performance and should not be the only consideration for investment. Dearborn Partners L.L.C. is an investment adviser registered under the Investment Advisers Act of 1940, as amended. Registration does not imply a certain level of skill or training. For a complete list of all Dearborn Rising Dividend holdings that in the past year - increased their dividends, had no dividend increases, or had a dividend decrease, please contact the Dearborn Rising Dividend Team at RD@dearbornpartners.com. It should not be assumed that portfolio trades made in the future will be profitable, or will increase their dividends, or will equal the performance of the securities in this announcement.